MEREO BIOPHARMA GROUP PLC Gain (Loss) on Derivative Instruments, Net, Pretax
MEREO BIOPHARMA GROUP PLC (MREO) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $6.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-06-30 was $6.00K.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-03-31 was $17.00K, a 95.91% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was $294.00K, a 87.26% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was $196.00K.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for fiscal 2025 was $805.00K.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for fiscal 2024 was -$419.00K, a 271.02% decline from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for fiscal 2023 was $245.00K, a 97.36% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC gain (loss) on derivative instruments, net, pretax for fiscal 2022 was $9.29M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.00K 10-Q · filed 2026-08-11 | $23.00K 10-Q · filed 2026-08-11 | $317.00K derived: sum of 3 quarters · filed 2026-08-11 | $513.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $17.00K 10-Q · filed 2026-05-12 | $311.00K derived: sum of 2 quarters · filed 2026-05-12 | $507.00K derived: sum of 3 quarters · filed 2026-05-12 | $406.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $490.00K derived: sum of 2 quarters · filed 2026-03-19 | $389.00K derived: sum of 3 quarters · filed 2026-08-11 | $805.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $196.00K 10-Q · filed 2025-11-10 | $95.00K derived: sum of 2 quarters · filed 2026-08-11 | $511.00K 10-Q · filed 2025-11-10 | $668.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$101.00K 10-Q · filed 2026-08-11 | $315.00K 10-Q · filed 2026-08-11 | $472.00K derived: sum of 3 quarters · filed 2026-08-11 | $413.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $416.00K 10-Q · filed 2026-05-12 | $573.00K derived: sum of 2 quarters · filed 2026-05-12 | $514.00K derived: sum of 3 quarters · filed 2026-05-12 | $445.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $98.00K derived: sum of 2 quarters · filed 2026-03-19 | $29.00K derived: sum of 3 quarters · filed 2026-03-19 | -$419.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$59.00K 10-Q · filed 2025-11-10 | -$128.00K derived: sum of 2 quarters · filed 2025-11-10 | -$576.00K 10-Q · filed 2025-11-10 | -$771.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$69.00K 10-Q · filed 2025-08-12 | -$517.00K 10-Q · filed 2025-08-12 | -$712.00K derived: sum of 3 quarters · filed 2025-08-12 | -$712.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$448.00K 10-Q · filed 2025-05-13 | -$643.00K derived: sum of 2 quarters · filed 2025-05-13 | -$643.00K derived: sum of 3 quarters · filed 2025-05-13 | -$745.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$195.00K derived: sum of 2 quarters · filed 2025-03-26 | -$297.00K derived: sum of 3 quarters · filed 2025-03-26 | $245.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | -$102.00K derived: sum of 2 quarters · filed 2024-11-12 | $440.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$102.00K 10-Q · filed 2024-08-13 | $440.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $542.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $9.29M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |